Ji 2023 - Mazdutide Phase 2 Trial in Chinese Adults With Overweight or Obesity

Nature Communications·December 14, 2023

Linong Ji, Hongwei Jiang, Zhifeng Cheng, Wei Qiu, Lin Liao, Yawei Zhang, Xiaoli Li, Shuguang Pang, Lihui Zhang, Liming Chen, Tao Yang, Yan Li, Shen Qu, Jie Wen, Jieyu Gu, Huan Deng, Yanqi Wang, Li Li, Han Han-Zhang, Qingyang Ma, Lei Qian

Summary

Mazdutide produced dose-dependent weight loss up to 11.3% at week 24 versus 1.0% weight gain with placebo in Chinese adults with overweight or obesity.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled trial

Indication

Overweight or obesity

Intervention

Once-weekly mazdutide 3 mg, 4.5 mg, or 6 mg vs placebo

Species

Human

Sample Size

248 subjects

Risk of Bias Assessment

Sponsor-funded by Innovent